Wound debridement products are used in the treatment and management of chronic ulcers, surgical wounds, traumatic wounds, and burns.  Wound debridement aids in removal of necrotic tissue and bacteria and senescent cells. Sharp surgical debridement resets the proper timing of the phases of wound reepithelialization.

North America wound debridement products market is estimated to account for US$ 223.4 Mn in terms of value in 2019 and is expected to reach US$ 378.3 Mn by the end of 2027.

North America Wound Debridement Products Market: Drivers

Increasing number of sports-related injuries is expected to boost growth of North America wound debridement products market. For instance, according to the National High School Sports-Related Injury Surveillance Study 2017-2018, 1,367,490 cases of sport-related were recorded in high schools in the U.S.

North America Wound Debridement Products Market: Opportunities 

Safer guidelines for reusable wound debridement products are expected to offer lucrative growth opportunities for players in the market. Reusable wound debridement products are cost-effective treatment options. However, risk of infection is limiting the use of these products.

North America Wound Debridement Products Market: Restraints

Use of wound debridement may lead to allergic reaction, which is expected to hamper growth of the market.  

Key Takeaways:

Chronic ulcers segment in North America wound debridement products market was valued at US$ 88.4 Mn in 2018 and is expected to reach US$ 175.1 Mn by 2027 at a CAGR of 8.2% during the forecast period. Chronic ulcers due to diabetes are on the rise in North America. For instance, according to American College of Physicians, 2017, lifetime incidence of foot ulcers in diabetic patients is between 19 to 34%.

The Mechanical Debridement Pads segment held dominant position in North America wound debridement products market in 2018, accounting for 29.8% share in terms of value. Several established manufacturers in the market such as B. Braun, Lohmann & Rauscher, and others offer these products in the market. Availability of variety of products, and widespread presence is expected to support growth of the segment.

The hospital segment held dominant position in North America wound debridement products market in 2018, accounting for 43.8% share in terms of value, followed by ambulatory surgical centers, and specialized clinics, respectively.

Market Trends

Players in the market are focused on adopting various marketing strategies to enhance their market share. For instance, in March 2020, MediWound Ltd., a biopharmaceutical company focused on developing products for severe burn and wound management, presented its portfolio at the Cowen and Company 40th Annual Healthcare Conference held in the U.S.

Increasing number of wound care centers is aiding in growth of the market. For instance, in September 2019, Baptist Health Corbin announce to start a Wound Care Center for the treatment of chronic or non-healing sores or wounds through debridement, specialty dressings, negative pressure therapies, bioengineering tissues and biosynthetic.



  • Policies and Regulations:
    • Governmental agencies and professional regulatory bodies are establishing limits and conditions on nurses scope of practice and developing directives, including CSWD. In Western Canada, because RNs are now covered by the Heath Professions Act, CSWD has been declared a “restricted activity” in Alberta and a “reserved action” in BC. Only those acts determined to pose significant risk to the public and legislated as “restricted” (or “reserved”) are “exclusive” in that only those professions who are authorized to perform each restricted activity may legally do so, based on individual practitioner competence. Ontario has similar legislation, with regulations under the Nursing Act and “controlled acts” authorized by the Regulated Health Professions Act, 1991.

North America Wound Debridement Products Market: Competitive Landscape

Major players operating in North America wound debridement products market include, Smith & Nephew plc, Zimmer Biomet, DeRoyal Industries, Inc., Lohmann & Rauscher International, Arobella Medical, LLC, Bactiguard AB, MediWound Ltd., Misonix, Inc., Söring GmbH, BSN Medical, and Derma Sciences Inc.

North America Wound Debridement Products Market: Key Developments  

March 2020: MediWound Ltd., a fully-integrated biopharmaceutical company, announced that the U.S. Biomedical Advanced Research and Development Authority expanded its contract with the company

December 2019: Misonix, Inc., a manufacturer of minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, announced publication of two new large real-world studies proving the clinical effectiveness of its all human split thickness skin allograft TheraSkin for the treatment of complex wounds


  • By Product Type
    • Hydrosurgical Debridement Devices
    • Low Frequency Ultrasound Devices
    • Surgical Wound Debridement Devices
    • Mechanical Debridement Pads
    • Traditional Wound Debridement Devices
    • Larval Therapy
  • By Application
    • Chronic Ulcers
    • Surgical Wounds
    • Traumatic Wounds
    • Burn Cases
  • By End User
    • Hospital
    • Ambulatory Surgical Centers
    • Specialized Clinics
    • Nursing Facilities
    • Others
  • By Country
    • U.S.
    • Canada


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo